GO:0005021 vascular endothelial growth factor receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005021 describes the molecular function of combining with a VEGF ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.
• VEGFR activity is mediated by receptor tyrosine kinases including VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), which bind VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E.
• VEGF receptor activation controls angiogenesis, vascular permeability, and endothelial cell survival, and is dysregulated in cancer, retinopathies, and inflammatory diseases.
• Ligand binding specificity and receptor dimerization are critical for downstream signaling; VEGF Trap, ranibizumab, and bevacizumab neutralize VEGF ligands to block receptor activation.
• Small-molecule indolin-2-one derivatives inhibit VEGFR activity and are investigated as anticancer agents.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of VEGFR signaling in disease.
Description
Vascular endothelial growth factor receptor (VEGFR) activity, annotated as GO:0005021, is a molecular function that combines with a VEGF ligand and transmits the signal across the plasma membrane to initiate a change in cell activity. This activity is essential for angiogenesis, vascular development, and endothelial homeostasis, and its dysregulation contributes to cancer, ocular neovascular disorders, and inflammatory pathologies. VEGFRs are receptor tyrosine kinases that bind a family of secreted ligands including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E, and the specificity of these interactions determines downstream signaling outcomes. Therapeutically, blocking VEGFR activity with ligand traps or receptor inhibitors is a validated strategy in oncology and ophthalmology. Understanding the molecular mechanisms, key genes, and regulatory layers of VEGFR activity is therefore central to both basic vascular biology and translational research.
vascular endothelial growth factor receptor activity At A Glance
| GO ID | GO:0005021 |
|---|---|
| GO term | vascular endothelial growth factor receptor activity |
| Ontology | molecular_function |
| Synonym | VEGF receptor activity; VEGFR activity; VEGF-activated receptor activity; VEGF-A-activated receptor activity; VEGF-B-activated receptor activity; VEGF-C-activated receptor activity; VEGF-D-activated receptor activity; VEGF-E-activated receptor activity |
| Major function | Binding VEGF ligands and transmitting signals across the plasma membrane to initiate cellular responses |
| Major receptors | VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4) |
| Major ligands | VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E |
| Associated processes | Angiogenesis, vascular permeability, endothelial cell survival and migration |
| Disease relevance | Cancer, retinopathies, inflammatory and vascular disorders |
What Is GO:0005021?
GO:0005021 vascular endothelial growth factor receptor activity is defined as the molecular function of combining with a vascular endothelial growth factor (VEGF) receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity. In practice, this means a receptor on the cell surface binds a VEGF-family ligand, becomes activated, and triggers intracellular signaling that alters the behavior of the cell.
Why Is vascular endothelial growth factor receptor activity Important in Cell Biology?
VEGFR activity is a central node in vascular biology because it converts extracellular VEGF signals into intracellular programs that drive endothelial cell proliferation, migration, survival, and permeability. This function is required for normal development and wound healing, but when overactivated it promotes tumor angiogenesis and pathological neovascularization. Consequently, VEGFR activity is a major target for therapeutic antibodies, ligand traps, and small-molecule inhibitors, and it remains a focus for CRISPR-based functional genomics.
• Controls angiogenesis and vascular development.
• Regulates vascular permeability and endothelial barrier function.
• Mediates endothelial cell survival, proliferation, and migration.
• Dysregulated in solid tumors and hematological malignancies.
• Implicated in ocular neovascular diseases such as retinopathies.
• Targeted by anti-VEGF biologics and VEGFR kinase inhibitors.
• Modulated by extracellular matrix components.
• Interacts with Tie family receptor tyrosine kinases.
• Expressed in trophoblast and choriocarcinoma cells, relevant to placental biology.
• Serves as a model for receptor tyrosine kinase signaling and drug discovery.
What Happens During vascular endothelial growth factor receptor activity?
Ligand binding and receptor dimerization
In simple terms: A VEGF ligand grabs onto a VEGFR on the cell surface, causing two receptors to pair up.
VEGF ligands bind to the extracellular domains of VEGFRs, promoting receptor dimerization and activation. Different ligands show distinct receptor preferences; for example, VEGF-A binds VEGFR1 and VEGFR2, while VEGF-C and VEGF-D bind VEGFR3. This binding specificity is a key determinant of downstream signaling.
Receptor autophosphorylation and kinase activation
In simple terms: Once paired, the receptors switch on their enzymatic activity by adding phosphate groups to themselves.
Ligand-induced dimerization activates the intrinsic tyrosine kinase activity of VEGFRs, leading to autophosphorylation of intracellular domains. These phosphorylated tyrosines serve as docking sites for signaling adaptors and enzymes that propagate the signal.
Downstream signaling cascades
In simple terms: The activated receptor sends signals inside the cell that tell it to grow, move, or survive.
Activated VEGFRs engage multiple pathways, including MAPK/ERK, PI3K/AKT, and nitric oxide signaling, to drive endothelial cell proliferation, migration, and survival. VEGFR1 signaling can modulate angiogenesis via nitric oxide production. VEGF also activates Tie family receptor tyrosine kinases, integrating with broader vascular signaling networks.
Cellular outcomes and feedback
In simple terms: The cell responds by forming new blood vessels or changing its behavior, and the signal is eventually tuned down.
VEGFR activity leads to angiogenesis, increased vascular permeability, and endothelial cell survival. Extracellular matrix components can control VEGF angiogenic activity, providing an additional layer of regulation. Receptor internalization and negative feedback mechanisms attenuate signaling to prevent excessive activation.
Key Genes Involved in GO:0005021 vascular endothelial growth factor receptor activity
The following genes encode the principal receptors, ligands, and signaling components associated with GO:0005021 vascular endothelial growth factor receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FLT1 (VEGFR1) | Binds VEGF-A, VEGF-B, and placental growth factor; modulates angiogenesis | Target for anti-VEGFR1 antibodies in cancer; regulates nitric oxide signaling |
| KDR (VEGFR2) | Primary receptor for VEGF-A; mediates angiogenesis and permeability | Central to endothelial signaling; target of kinase inhibitors |
| FLT4 (VEGFR3) | Binds VEGF-C and VEGF-D; regulates lymphangiogenesis | Implicated in lymphatic development and cancer |
| VEGFA | Major ligand for VEGFR1 and VEGFR2 | Neutralized by bevacizumab and ranibizumab |
| VEGFB | Ligand for VEGFR1 | Involved in lipid metabolism and vascular maintenance |
| VEGFC | Ligand for VEGFR3 and VEGFR2 | Regulates lymphangiogenesis |
| VEGFD | Ligand for VEGFR3 | Involved in lymphatic vessel growth |
| PGF (PlGF) | Ligand for VEGFR1 | Modulates angiogenesis and inflammation |
| TIE1 | Receptor tyrosine kinase activated by VEGF | Integrates VEGF and angiopoietin signaling |
| TEK (TIE2) | Receptor tyrosine kinase activated by VEGF | Vascular stabilization and angiogenesis |
| NOS3 (eNOS) | Produces nitric oxide downstream of VEGFR1 | Mediates VEGF-induced angiogenesis |
| SRC | Signaling adaptor downstream of VEGFR2 | Regulates vascular permeability |
| PIK3CA | PI3K subunit in VEGFR signaling | Cell survival and migration |
| MAPK1 (ERK2) | Kinase in MAPK cascade downstream of VEGFR | Proliferation signaling |
| AKT1 | Serine/threonine kinase in PI3K pathway | Endothelial survival |
| HIF1A | Transcription factor inducing VEGFA expression | Hypoxia-driven angiogenesis |
| NRP1 | Co-receptor for VEGF-A | Enhances VEGFR2 signaling |
| NRP2 | Co-receptor for VEGF-C and VEGF-D | Lymphangiogenesis |
How Is vascular endothelial growth factor receptor activity Regulated?
VEGFR activity is regulated at multiple levels. Ligand availability is controlled by extracellular matrix components that can sequester or present VEGF. Receptor activation is balanced by internalization, degradation, and negative feedback loops. Nitric oxide produced downstream of VEGFR1 can modulate angiogenic responses. Additionally, VEGF can activate Tie family receptors, indicating cross-talk between VEGFR and other receptor tyrosine kinase pathways. Pharmacological regulation includes ligand sequestration by VEGF Trap, ranibizumab, and bevacizumab, and inhibition of receptor kinase activity by small molecules such as indolin-2-one derivatives.
vascular endothelial growth factor receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KDR (VEGFR2) | Tumor angiogenesis | Knockout endothelial cells; xenograft models |
| FLT1 (VEGFR1) | Cancer, inflammation | Anti-VEGFR1 antibody treatment in cancer models |
| VEGFA | Ocular neovascularization, cancer | Ligand neutralization with bevacizumab/ranibizumab |
| NOS3 (eNOS) | VEGF-mediated angiogenesis | Knockout or point-mutation models |
| FLT4 (VEGFR3) | Lymphangiogenesis, cancer | Knock-in reporter for VEGFR3 expression |
Cancer and tumor angiogenesis
VEGFR activity drives tumor angiogenesis, supplying oxygen and nutrients to growing tumors. Anti-VEGFR1 antagonist antibodies have shown therapeutic potential in cancer models. Small-molecule VEGFR inhibitors, including indolin-2-one derivatives, are being developed as anticancer agents. VEGF Trap, ranibizumab, and bevacizumab neutralize VEGF ligands and block receptor activation, and are used in oncology and ophthalmology.
Ocular neovascular diseases
Excessive VEGFR signaling contributes to pathological neovascularization in the eye, and VEGF-neutralizing agents such as ranibizumab and VEGF Trap are used to treat these conditions.
Placental and trophoblast biology
VEGFR localization and activation have been demonstrated in human trophoblast and choriocarcinoma cells, implicating VEGFR activity in placental development and related pathologies.
Inflammatory and vascular disorders
VEGFR1 modulates angiogenesis via nitric oxide, linking VEGFR activity to inflammatory and vascular permeability disorders. Extracellular matrix control of VEGF angiogenic activity further influences disease progression.
From vascular endothelial growth factor receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of VEGFR2 abolish angiogenesis? | CRISPR knockout of KDR in endothelial cells |
| Does a specific VEGFR2 point mutation alter kinase activity? | CRISPR point mutation knock-in |
| How does VEGFR1 modulate nitric oxide signaling? | Knockout or overexpression of FLT1 |
| Can VEGFR3 be tracked in live cells? | Tagged knock-in of FLT4 |
| Does overexpression of VEGFA drive tumor growth? | CRISPR overexpression models |
| Which genes mediate resistance to VEGFR inhibitors? | CRISPR library screening |
How to Study the vascular endothelial growth factor receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Determine requirement for VEGFR genes in angiogenesis |
| CRISPR point mutation | Specific amino acid changes | Dissect kinase activity or phosphorylation sites |
| Knock-in reporter | Receptor localization and dynamics | Live-cell imaging of VEGFR trafficking |
| Overexpression | Gain of function | Model pathological VEGFR activation |
| CRISPR library screening | Phenotypic modifiers | Identify resistance or synthetic lethal genes |
| RNA-seq | Transcriptional changes | Profile downstream gene expression |
| Proteomics | Protein interactions and modifications | Map VEGFR signaling complexes |
| Immunofluorescence | Protein localization | Validate receptor expression in tissues |
CRISPR knockout and point-mutation models
CRISPR knockout of VEGFR genes (FLT1, KDR, FLT4) enables loss-of-function studies to determine their role in angiogenesis and disease. Point-mutation knock-in can dissect specific phosphorylation sites or kinase-domain residues.
Knock-in reporters and tagging
Tagged knock-in of VEGFR genes allows real-time imaging of receptor localization and trafficking. This approach is useful for studying receptor internalization and downstream signaling.
Overexpression and ligand neutralization
Overexpression of VEGF ligands or receptors can model pathological activation. Conversely, ligand traps and neutralizing antibodies block VEGFR activity and are used to validate target dependency.
Library screening and bioinformatics
CRISPR library screening can identify modifiers of VEGFR signaling and resistance mechanisms to VEGFR inhibitors. Bioinformatics analysis of transcriptomic and proteomic data helps prioritize candidate genes in the VEGFR pathway.
How CRISPR Can Be Used to Study GO:0005021 vascular endothelial growth factor receptor activity
Knockout
CRISPR knockout of VEGFR genes such as KDR or FLT1 can abolish receptor activity and is used to test causality in angiogenesis and cancer models.
Point Mutation
Point-mutation knock-in allows precise modification of kinase-domain residues to study how specific mutations alter VEGFR activity and downstream signaling.
Knock-in
Knock-in of tags or reporters into VEGFR loci enables visualization of receptor expression and trafficking in live cells.
Overexpression
CRISPR overexpression of VEGF ligands or receptors can model gain-of-function states relevant to cancer and vascular disease.
How EDITGENE Supports vascular endothelial growth factor receptor activity Research
Researchers studying vascular endothelial growth factor receptor activity-related genes often need to determine whether a candidate gene is causally involved in angiogenesis, vascular permeability, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for vascular endothelial growth factor receptor activity research.
Frequently Asked Questions About vascular endothelial growth factor receptor activity
What is vascular endothelial growth factor receptor activity?
It is a molecular function (GO:0005021) where a receptor binds a VEGF ligand and transmits a signal across the plasma membrane to initiate a change in cell activity.
What genes are involved in vascular endothelial growth factor receptor activity?
Key genes include FLT1 (VEGFR1), KDR (VEGFR2), FLT4 (VEGFR3), and ligands such as VEGFA, VEGFB, VEGFC, VEGFD, and PGF.
What is the GO ID for vascular endothelial growth factor receptor activity?
The GO ID is GO:0005021.
Which diseases are linked to VEGFR activity?
VEGFR activity is linked to cancer, ocular neovascular diseases, and inflammatory vascular disorders.
How is VEGFR activity inhibited therapeutically?
It can be blocked by ligand traps such as VEGF Trap, neutralizing antibodies like bevacizumab and ranibizumab, or small-molecule kinase inhibitors.
What experimental models are used to study VEGFR activity?
CRISPR knockout, point-mutation, knock-in reporters, overexpression, and library screening are commonly used.
Does VEGF activate other receptors besides VEGFR?
Yes, VEGF can activate Tie family receptor tyrosine kinases such as TIE1 and TEK.
How does extracellular matrix affect VEGFR activity?
Extracellular matrix components can control VEGF angiogenic activity by modulating ligand availability and presentation.
Is VEGFR activity important in placental biology?
Yes, VEGFR localization and activation have been demonstrated in human trophoblast and choriocarcinoma cells.
What is the role of nitric oxide in VEGFR signaling?
VEGFR1 can modulate angiogenesis via nitric oxide production, influencing vascular responses.
Conclusion
GO:0005021 vascular endothelial growth factor receptor activity is a fundamental molecular function that converts VEGF signals into cellular responses driving angiogenesis, vascular permeability, and endothelial survival. Its dysregulation is central to cancer, ocular neovascular diseases, and inflammatory disorders, making it a prime therapeutic target. CRISPR-based models, including knockout, point-mutation, knock-in, and overexpression, provide powerful tools to dissect VEGFR biology and accelerate drug discovery.
References
- 1. Papadopoulos N et al.. 2012. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.. Angiogenesis 15(2):171-85 PMID: 22302382
- 2. Yousefian M et al.. 2020. Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents.. Arch Pharm (Weinheim) 353(12):e2000022 PMID: 32885522
- 3. Zachary I. 1998. Vascular endothelial growth factor.. Int J Biochem Cell Biol 30(11):1169-74 PMID: 9839443
- 4. Singh H et al.. 2009. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases.. Cell Signal 21(8):1346-50 PMID: 19376222
- 5. Charnock-Jones DS et al.. 1994. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells.. Biol Reprod 51(3):524-30 PMID: 7803624
- 6. Wu Y et al.. 2006. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.. Clin Cancer Res 12(21):6573-84 PMID: 17085673
- 7. Ortéga N et al.. 1998. Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix.. Biol Cell 90(5):381-90 PMID: 9835012
- 8. Bussolati B et al.. 2001. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.. Am J Pathol 159(3):993-1008 PMID: 11549592
